MELBOURNE, AUSTRALIA / ACCESSWIRE / July 6, 2015 / Propanc Health Group Corporation (PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced that it has entered into a biomarker discovery agreement with Adaptive Biotechnologies, Seattle, WA, USA.

Under the agreement, Adaptive will use its patented immune profiling assay, the immunoSEQ(R) Assay, to enable an in-depth characterization of the immune response to diseases being studied in both the pre-clinical setting and in later clinical development efforts focused on Propanc’s proteolytic pro-enzyme “PRP” therapeutic. The exploration of immune responses in the peri-cellular (i.e. outside the cell) tumor microenvironment, where PRP is thought to play a role, may identify patient populations more likely to respond to therapy based on their immune status.

“We are very pleased to be entering into this important research with Adaptive Biotechnologies,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Adaptive is right at the forefront of the immuno-oncology space. We look forward to learning more about PRP, its underlying mechanisms, how it influences the environment around the cancer cell, and importantly, a patient’s immune response to treatment. This will support the development of PRP, as well as the Company’s ongoing research discovery programs.”

“As the leader in immunosequencing, Adaptive is poised to work closely with companies like Propanc to help drive such unique innovation and discovery in cancer therapeutics,” said Chad Robins, Adaptive’s President, Chief Executive Officer and Co-Founder. “Our technology continues to demonstrate the importance of elucidating the adaptive immune system and how this knowledge is a pivotal component to understanding a patient’s response to new treatments, ultimately improving patient care worldwide.”

About Adaptive Biotechnologies:

Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive ground-breaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.

About Propanc:

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Propanc have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc’s products involve or employ proenzymes, which are inactive precursors of enzymes.

In the near term, Propanc intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors.In future, Propanc intend to development their lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.

Forward-looking Statements:

Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company’s ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company’s financial position. See Propanc’s most recent Quarterly Report on Form 10-Q and related 8K filings.